Cargando…
A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer
BACKGROUND: The information of Oncotype DX applied in Asian breast cancer patients is limited. A recurrence index for distant recurrence (RI-DR) has been developed for early-stage breast cancer (EBC) from tumor samples in Chinese patients. In this study, we compared the prognostic performance of the...
Autores principales: | Yang, Po-Sheng, Lee, Yi-Hsuan, Chung, Chi-Feng, Chang, Yuan-Ching, Wang, Ming-Yang, Lo, Chiao, Tsai, Li Wei, Shih, Kuan-Hui, Lei, Jason, Yu, Ben-Long, Cheng, Skye H, Huang, Chiun-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918807/ https://www.ncbi.nlm.nih.gov/pubmed/31287883 http://dx.doi.org/10.1093/jjco/hyz102 |
Ejemplares similares
-
Prognostic Comparison between Oncotype DX(®) and a 23-Gene Classifier, RecurIndex(®), on the Taiwan Breast Cancer Population
por: Chang, Chuan-Hsun, et al.
Publicado: (2022) -
The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016) -
Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018) -
Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017) -
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)